- Home
- VERU vs AGEN Comparison
VERU vs AGEN Comparison
Compare VERU & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERU
- AGEN
- Stock Information
- Founded
- VERU 1971
- AGEN 1994
- Country
- VERU United States
- AGEN United States
- Employees
- VERU N/A
- AGEN N/A
- Industry
- VERU Biotechnology: Pharmaceutical Preparations
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VERU Health Care
- AGEN Health Care
- Exchange
- VERU Nasdaq
- AGEN Nasdaq
- Market Cap
- VERU 108.8M
- AGEN 96.2M
- IPO Year
- VERU 1990
- AGEN 2000
- Fundamental
- Price
- VERU $0.98
- AGEN $3.48
- Analyst Decision
- VERU Strong Buy
- AGEN Buy
- Analyst Count
- VERU 4
- AGEN 3
- Target Price
- VERU $4.00
- AGEN $10.50
- AVG Volume (30 Days)
- VERU 2.2M
- AGEN 419.4K
- Earning Date
- VERU 02-06-2025
- AGEN 03-13-2025
- Dividend Yield
- VERU N/A
- AGEN N/A
- EPS Growth
- VERU N/A
- AGEN N/A
- EPS
- VERU N/A
- AGEN N/A
- Revenue
- VERU $16,886,419.00
- AGEN $160,427,000.00
- Revenue This Year
- VERU N/A
- AGEN N/A
- Revenue Next Year
- VERU N/A
- AGEN $36.13
- P/E Ratio
- VERU N/A
- AGEN N/A
- Revenue Growth
- VERU 3.62
- AGEN 59.00
- 52 Week Low
- VERU $0.36
- AGEN $2.50
- 52 Week High
- VERU $1.92
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- VERU 74.65
- AGEN 58.60
- Support Level
- VERU $0.70
- AGEN $3.08
- Resistance Level
- VERU $0.81
- AGEN $3.29
- Average True Range (ATR)
- VERU 0.11
- AGEN 0.26
- MACD
- VERU 0.02
- AGEN 0.05
- Stochastic Oscillator
- VERU 95.26
- AGEN 80.36
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).